Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Vranckx

Showing results (231-240 of 305) with videos related to

Pageof 31
Sort By:
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 10, 2019
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trialKuniaki Takahashi, Ply Chichareon, Rodrigo Modolo, et al.
JACC. Cardiovascular Interventions|April 12, 2023
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT TrialAntonio Landi, Dik Heg, Enrico Frigoli, et al.
The Canadian Journal of Cardiology|March 7, 2020
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERSAna Paula de Faria, Rodrigo Modolo, Ply Chichareon, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|June 23, 2012
A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 yearsPatrick W Serruys, Vasim Farooq, Pascal Vranckx, et al.
American Heart Journal|September 5, 2024
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trialEmmanuel De Cock, Shakeel Kautbally, Frank Timmermans, et al.
Circulation. Cardiovascular Interventions|August 26, 2020
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary InterventionHironori Hara, Kuniaki Takahashi, Norihiro Kogame, et al.
European Heart Journal|August 10, 2019
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trialPatrick W Serruys, Kuniaki Takahashi, Ply Chichareon, et al.
Pageof 31

Showing results (231-240 of 305) with videos related to

Sort By:
Pageof 31
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 10, 2019
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trialKuniaki Takahashi, Ply Chichareon, Rodrigo Modolo, et al.
JACC. Cardiovascular Interventions|April 12, 2023
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT TrialAntonio Landi, Dik Heg, Enrico Frigoli, et al.
The Canadian Journal of Cardiology|March 7, 2020
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERSAna Paula de Faria, Rodrigo Modolo, Ply Chichareon, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|June 23, 2012
A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 yearsPatrick W Serruys, Vasim Farooq, Pascal Vranckx, et al.
American Heart Journal|September 5, 2024
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trialEmmanuel De Cock, Shakeel Kautbally, Frank Timmermans, et al.
Circulation. Cardiovascular Interventions|August 26, 2020
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary InterventionHironori Hara, Kuniaki Takahashi, Norihiro Kogame, et al.
European Heart Journal|August 10, 2019
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trialPatrick W Serruys, Kuniaki Takahashi, Ply Chichareon, et al.
Pageof 31